Pharmacological treatment of chronic diabetes by stimulating pancreatic beta-cell regeneration with systemic co-administration of EGF and gastrin.
about
Concise review: pancreas regeneration: recent advances and perspectivesThe relation among NGF, EGF and insulin is important for triggering pancreatic β cell apoptosisCombination treatment of db/db mice with exendin-4 and gastrin preserves β-cell mass by stimulating β-cell growth and differentiation.Betacellulin-induced beta cell proliferation and regeneration is mediated by activation of ErbB-1 and ErbB-2 receptors.Baicalein Protects against Type 2 Diabetes via Promoting Islet β-Cell Function in Obese Diabetic Mice.Pancreatic insulin-producing cells differentiated from human embryonic stem cells correct hyperglycemia in SCID/NOD mice, an animal model of diabetesClinical islet transplant: current and future directions towards tolerance.Approaches towards endogenous pancreatic regenerationBeta Cell Mass Restoration in Alloxan-Diabetic Mice Treated with EGF and GastrinOreocnide integrifolia Flavonoids Augment Reprogramming for Islet Neogenesis and β-Cell Regeneration in Pancreatectomized BALB/c Mice.The pancreatic ductal epithelium serves as a potential pool of progenitor cells.Methods of human islet culture for transplantation.Identification and expansion of pancreatic stem/progenitor cells.Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD miceOmeprazole and PGC-formulated heparin binding epidermal growth factor normalizes fasting blood glucose and suppresses insulitis in multiple low dose streptozotocin diabetes model.Prospects and challenges for islet regeneration as a treatment for diabetes: a review of islet neogenesis associated protein.Epidermal growth factor increases insulin secretion and lowers blood glucose in diabetic micePancreatic islet culture and preservation strategies: advances, challenges, and future outlook.Gastrointestinal hormones and the regulation of β-cell mass.Pancreatic β-Cell Mass as a Pharmacologic Target in Diabetes.Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides.Proton pump inhibitors: impact on glucose metabolism.Bi-stability in type 2 diabetes mellitus multi-organ signalling network.Pancreatic islet immunoreactivity to the Reg protein INGAP.Differentiation of fetal pancreatic stem cells into neuron-like and islet-like cells in vitro.Effects of atorvastatin on the regeneration of pancreatic {beta}-cells after streptozotocin treatment in the neonatal rodent.Culturing with modified EGM2 medium enhances porcine neonatal islet-like cell clusters resistance to apoptosis in islet xenotransplantation.Activation of GLP-1 and gastrin signalling induces in vivo reprogramming of pancreatic exocrine cells into beta cells in mice.Mixed chimerism and growth factors augment β cell regeneration and reverse late-stage type 1 diabetes.The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment.
P2860
Q27013646-DC2C1C4E-FDEC-4DFA-9163-F55E2E16AAEFQ28564708-A7E19396-E69A-4910-A16E-77DBB574A63EQ33609727-AB346115-441C-4897-ABA5-9072DD2A46FCQ34012804-90F1BA2E-2976-4B01-8DA5-C90611D04A10Q34043054-D22C9072-8E4D-47C7-9564-104124B23E1EQ35204266-1471AF1F-5353-458D-8483-ACB21C5621E8Q35583539-DABAECB4-72F3-46FC-83C2-24439CDBFB9BQ35612701-1A18B23A-5E45-4CA8-A978-8CAC5CD457D2Q35801749-6932E2D1-AA0A-46F5-BE93-365CD0329EAAQ35830295-A92BB832-72C4-4FB3-8803-3FEAFC4B466FQ35985286-7FEF9FDA-4172-443C-9EBB-725914674B41Q36008369-F26D8348-9DB4-4D38-A063-C6EF6B2E9B53Q36166499-51152F26-A2E7-4695-AC44-9432CC2D9767Q36228938-E9EFA165-E325-4B8F-80FD-4EC7B5952FF9Q37238824-C1FED451-F926-435C-A254-A1E1EDC19508Q37407901-19A17217-9DDA-478E-BEDF-51CE4236B545Q37568726-BA5FAC4B-8460-4543-9A77-FFCB213A4283Q37780808-9E2F28EA-B2CB-4D33-9ECB-D37024AF6394Q37805600-3E8F3B07-8494-4D2A-82F9-D56B9F2BA939Q37832150-051DDAB4-5329-4C12-9B90-575B8DB1652DQ37851584-7E787936-CE5F-46DD-AAE7-E05A91467931Q38034083-457DB454-A15C-4041-B9CA-58F7BD377DC4Q38646688-D117FFE8-BDAF-4E76-B245-3BA318B91355Q40052893-26D7ECB4-CC9D-43F8-B1BD-084E08084A81Q42136515-F92D4FE9-AE9D-4CC5-A3F9-89299A995E3EQ43100960-B89840BC-3ED7-4018-B1B6-A25F90E07FCDQ45874376-0DD761E1-D71F-455C-88FB-758BBEE045FFQ46185294-1EDBB576-1F8E-4979-950A-D0B47D38C818Q47568710-05A27660-1847-4EAB-AE42-1AFB6FAF1A37Q47695204-F231E8F3-A0BC-4065-B89E-2C60EE2E5C8E
P2860
Pharmacological treatment of chronic diabetes by stimulating pancreatic beta-cell regeneration with systemic co-administration of EGF and gastrin.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacological treatment of c ...... nistration of EGF and gastrin.
@ast
Pharmacological treatment of c ...... nistration of EGF and gastrin.
@en
type
label
Pharmacological treatment of c ...... nistration of EGF and gastrin.
@ast
Pharmacological treatment of c ...... nistration of EGF and gastrin.
@en
prefLabel
Pharmacological treatment of c ...... nistration of EGF and gastrin.
@ast
Pharmacological treatment of c ...... nistration of EGF and gastrin.
@en
P2093
P1476
Pharmacological treatment of c ...... nistration of EGF and gastrin.
@en
P2093
Kathryn Doiron
Krystyna Tatarkiewicz
Philip Lambert
Sheila G Magil
Stephen J Brand
Sven Tagerud
Yanhua Yan
P2860
P304
P356
10.1034/J.1600-0773.2002.910621.X
P577
2002-12-01T00:00:00Z